着床前遺伝学的検査市場：技術、提供、手順タイプ、用途、エンドユーザー別-世界予測2025-2030年

着床前遺伝学的検査市場は、2023年に7億2,840万米ドルと評価され、2024年には8億2,906万米ドルに達すると予測され、CAGR 14.56％で成長し、2030年には18億8,628万米ドルになると予測されています。

着床前遺伝学的検査（PGT）は、生殖補助医療において着床前の胚に遺伝性疾患がないか調べるために用いられる最先端の検査法で、遺伝性疾患のリスクを減らすことを目的としています。PGTの必要性は、特に遺伝性疾患の既往歴のある人に対する遺伝性疾患の予防と健康的な妊娠転帰に対する要求の高まりから生じています。PGTの主な用途は、不妊治療クリニックや体外受精（IVF）サービスを提供する病院です。最終用途の範囲は、遺伝子変異を受け継ぐリスクのあるカップルから、妊娠損失を繰り返しているカップルや体外受精を受けているカップルまで多岐にわたる。この市場の主な成長要因としては、不妊率の上昇、遺伝子技術の進歩、遺伝性疾患に対する意識の高まり、遺伝情報に基づいた生殖選択の受容の高まりなどが挙げられます。研究開発への投資が継続的に注ぎ込まれ、技術革新と市場拡大の原動力となっており、個別化医療とプレシジョン・ヘルスケアが牽引役となっています。非侵襲的なスクリーニング技術や強化された遺伝子解析ツールをめぐっては、企業にとって技術革新の機会が存在し、リスクが低く精度が高いため、採用が拡大する可能性があります。しかし、倫理的配慮、高コスト、厳格な規制、発展途上地域における認知度の低さなどの制約があります。これらの要因を克服するためには、広範な教育イニシアティブと戦略的パートナーシップにより、普及と手頃な価格での導入を推進する必要があります。市場関係者は、PGTの有効性と安全性を高めつつコストを削減することを目的とした強力な研究開発活動に注力することができます。さらに、データ分析における人工知能の統合を模索することで、プロセスを合理化し、予測精度を向上させることができます。学術機関との連携を重視すれば、重要なイノベーションに拍車がかかるかもしれないです。企業はまた、消費者層を広げるために、倫理的な懸念に対処しつつ、サービスの利用しやすさを高める政策を提唱すべきです。このような道筋に集中することで、企業は進化するPGTの情勢において競合優位に立つことができます。

市場力学：急速に進化する着床前遺伝学的検査市場の主要市場インサイトを公開

着床前遺伝学的検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 胎児異常の大幅な発生と、健康で成功する胚移植の必要性
  • 世界の不妊症の増加と不妊治療クリニックの増加
  • 遺伝性疾患の治療に対する政府支援の増加と相まって、早期診断アプローチの増加
• 市場抑制要因
  • PGTに伴う制限とリスク
• 市場機会
  • 着床前遺伝子解析分野における技術の進歩
  • 新興企業のエコシステムと着床前遺伝学的検査分野への投資
• 市場の課題
  • 倫理的制約とPGTの悪用

ポーターの5つの力：着床前遺伝学的検査市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、着床前遺伝学的検査市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：着床前遺伝学的検査市場における外部からの影響の把握

外部マクロ環境要因は、着床前遺伝学的検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析着床前遺伝学的検査市場における競合情勢の把握

着床前遺伝学的検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス着床前遺伝学的検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、着床前遺伝学的検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 胎児異常の発生率が高く、健康で正常な胚移植が必要である
    • 不妊率の増加と不妊治療クリニックの世界の増加
    • 早期診断アプローチの拡大と遺伝性疾患治療に対する政府支援の増加
  • 抑制要因
    • PGTに伴う制限とリスク
  • 機会
    • 着床前遺伝子解析分野における技術の進歩
    • 着床前遺伝学的検査分野における新興スタートアップエコシステムと投資
  • 課題
    • PGTの倫理的制約と誤用
• 市場セグメンテーション分析
  • 技術：染色体異常や単一遺伝子疾患を検出するための次世代シーケンシングの進歩
  • 提供内容：多様なサービスを活用してプロセス条件を最適化し、正確な結果を導きます
  • 手順：遺伝性疾患のリスクを減らすために着床前遺伝子診断（PGD）手順の導入を増やす
  • 応用：異数性疾患に対する着床前遺伝学的検査の幅広い利用
  • エンドユーザー：正確な診断と効果的な治療のために、ヘルスケア調査機関におけるPGTの採用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 着床前遺伝学的検査市場：技術別

• 比較ゲノムハイブリダイゼーション
• 蛍光in-situハイブリダイゼーション
• 次世代シーケンシング
• ポリメラーゼ連鎖反応
• 一塩基多型

第7章 着床前遺伝学的検査市場：提供別

• 機器
• 試薬・消耗品
• ソフトウェアとサービス

第8章 着床前遺伝学的検査市場手順の種類別

• 着床前遺伝子診断
• 着床前遺伝子スクリーニング

第9章 着床前遺伝学的検査市場：用途別

• 異数性
• 性別の認識
• HLAタイピング
• 単一遺伝子疾患
• 染色体構造異常
  • 削除
  • 重複
  • 反転
  • 転座
• X連鎖疾患

第10章 着床前遺伝学的検査市場：エンドユーザー別

• 契約調査・製造組織
• クライオバンク
• 病院、診断ラボ、サービスプロバイダー
• 調査室および学術機関

第11章 南北アメリカの着床前遺伝学的検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の着床前遺伝学的検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの着床前遺伝学的検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ナテラ社、患者サービスと市場ポジション強化のため、インビテー社から出生前スクリーニングとキャリアスクリーニングの資産を買収
  • サーモフィッシャーサイエンティフィックは、着床前遺伝子検査用の高度なシーケンシングツールを発売し、不妊調査と生殖医療の成果を向上させます。
  • メディカバー・ジェネティクスとフィムラボ・ラボラトリーズ、フィンランドで遺伝子検査サービスを提供する提携を発表
  • 米国FertilityとOvationが合併してIVFサービスの大手企業となり、不妊治療サービスへのアクセスが向上
  • ユーロフィンズ・ジェノマ、非侵襲性、胚生検不要、着床前遺伝子異数性スクリーニング検査「niPGT-A」の発売を発表
  • GenEmbryomicsがこれまでで最も包括的なIVF遺伝子検査を導入
  • 体外受精を受けるシンガポール人が、いくつかの種類の治療に新たな資金援助を受ける
  • オーストラリアのフェルティリス社が体外受精の胚培養を自動化するため200万米ドルを調達

企業一覧

• Abbott Laboratories
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Bioarray S.L.
• EUROPE IVF International s.r.o.
• F. Hoffmann-La Roche AG
• Genea Limited
• GENETiKS
• Illumina, Inc.
• Invicta Genetics
• Invitae Corporation
• Juno Genetics, US Inc.
• Laboratory Corporation of America Holdings
• MedGenome Labs Ltd.
• Merck KGaA
• Natera, Inc.
• NextGen Genetics Holdings, LLC
• Ovation Fertility
• PacGenomics
• PerkinElmer, Inc.
• Progyny, Inc.
• Qiagen N.V.
• Quest Diagnostics Incorporated
• Reproductive Genetic Innovations, LLC
• SEQUENCE46, LLC
• Sysmex Corporation
• Takara Bio Inc.
• The Cooper Companies Inc.
• Thermo Fisher Scientific Inc.
• Vitrolife Sweden AB
• Yikon Genomics（Shanghai）Co., Ltd.

LIST OF FIGURES

• FIGURE 1. PREIMPLANTATION GENETIC TESTING MARKET RESEARCH PROCESS
• FIGURE 2. PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PREIMPLANTATION GENETIC TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GENDER IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DELETIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DUPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INVERSIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TRANSLOCATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY X-LINKED DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CRYOBANKS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, DIAGNOSTIC LABS, & SERVICE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 58. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 61. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 87. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 90. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 91. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 93. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 96. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 97. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 99. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 105. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 111. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 117. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 123. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 129. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 135. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 141. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 147. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 153. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 166. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 172. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 178. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 184. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 190. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 196. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 197. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 198. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 199. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 200. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 201. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 202. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 207. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 208. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 214. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 219. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 220. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 221. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 222. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 223. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 224. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 225. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 226. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 227. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 228. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 229. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 230. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 231. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 232. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 237. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 238. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 243. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 244. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 250. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 255. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 256. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 261. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 262. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 267. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 268. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 273. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 274. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 279. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 280. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
• TABLE 284. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 285. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2030 (USD MILLION)
• TABLE 286. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 287. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 288. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Preimplantation Genetic Testing Market was valued at USD 728.40 million in 2023, expected to reach USD 829.06 million in 2024, and is projected to grow at a CAGR of 14.56%, to USD 1,886.28 million by 2030.

Preimplantation Genetic Testing (PGT) is a cutting-edge procedure used to examine embryos for genetic diseases before implantation during assisted reproduction, aiming to reduce the risk of inherited conditions. Its necessity arises from the increasing demand for genetic disease prevention and healthy pregnancy outcomes, especially for individuals with a history of genetic disorders. The application of PGT predominantly lies in fertility clinics and hospitals that offer in vitro fertilization (IVF) services. The end-use scope ranges from couples at risk of passing on genetic mutations to those experiencing recurrent pregnancy losses or undergoing IVF. Key growth factors in this market include rising infertility rates, advances in genetic technologies, growing awareness about genetic disorders, and increasing acceptance of genetically informed reproductive choices. There is a continuous pour of investment in research and development, driving innovation and market expansion, with personalized medicine and precision healthcare gaining traction. Opportunities exist for businesses to innovate around non-invasive screening techniques and enhanced genetic analysis tools, representing the potential to widen adoption due to lower risks and increased accuracy. However, limitations include ethical considerations, high costs, strict regulations, and limited awareness in developing regions. Overcoming these factors requires extensive educational initiatives and strategic partnerships to drive adoption and affordability. Market players can focus on robust R&D efforts aimed at reducing costs while enhancing the efficacy and safety of PGT. Additionally, exploring the integration of artificial intelligence in data analysis could streamline processes and improve predictive accuracy. Emphasizing collaborations with academic institutions might spur key innovations. Businesses should also advocate for policies enhancing service accessibility while addressing ethical concerns to broaden their consumer base. By concentrating on these paths, firms can gain a competitive edge in the evolving landscape of PGT.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Preimplantation Genetic Testing Market

The Preimplantation Genetic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Significant incidences of fetal abnormalities and need for healthy and successful embryo implantation
  • Increase in the rate of infertility and the rising number of fertility clinics worldwide
  • Growing early diagnostic approaches coupled with increasing government support to treat genetic diseases
• Market Restraints
  • Limitation and risks associated with PGT
• Market Opportunities
  • Technological advancement in the field of preimplantation genetic analysis
  • Emerging startup ecosystem and investments in the field of preimplantation genetic testing
• Market Challenges
  • Ethical constraints and Misuse of PGT

Porter's Five Forces: A Strategic Tool for Navigating the Preimplantation Genetic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Preimplantation Genetic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Preimplantation Genetic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Preimplantation Genetic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Preimplantation Genetic Testing Market

A detailed market share analysis in the Preimplantation Genetic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Preimplantation Genetic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Preimplantation Genetic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Preimplantation Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Bioarray S.L., EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, Genea Limited, GENETiKS, Illumina, Inc., Invicta Genetics, Invitae Corporation, Juno Genetics, US Inc., Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Merck KGaA, Natera, Inc., NextGen Genetics Holdings, LLC, Ovation Fertility, PacGenomics, PerkinElmer, Inc., Progyny, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, LLC, SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., The Cooper Companies Inc., Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Preimplantation Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Comparative Genomic Hybridization, Fluorescence in-Situ Hybridization, Next-Generation Sequencing, Polymerase Chain Reaction, and Single-Nucleotide Polymorphism.
• Based on Offering, market is studied across Instruments, Reagents & Consumables, and Software & Services.
• Based on Procedure Type, market is studied across Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening.
• Based on Application, market is studied across Aneuploidy, Gender Identification, HLA Typing, Single Gene Disorders, Structural Chromosomal Abnormalities, and X-Linked Disorders. The Structural Chromosomal Abnormalities is further studied across Deletions, Duplications, Inversions, and Translocations.
• Based on End User, market is studied across Contract Research & Manufacturing Organizations, Cryobanks, Hospitals, Diagnostic Labs, & Service Providers, and Research Laboratories & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Significant incidences of fetal abnormalities and need for healthy and successful embryo implantation
    • 5.1.1.2. Increase in the rate of infertility and the rising number of fertility clinics worldwide
    • 5.1.1.3. Growing early diagnostic approaches coupled with increasing government support to treat genetic diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Limitation and risks associated with PGT
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancement in the field of preimplantation genetic analysis
    • 5.1.3.2. Emerging startup ecosystem and investments in the field of preimplantation genetic testing
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical constraints and Misuse of PGT
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Advancements in next-generation sequencing to detect chromosomal abnormalities and single-gene disorders
  • 5.2.2. Offering: Utilization of diverse offerings to optimize process conditions and derive accurate results
  • 5.2.3. Procedure: Increasing deployment of preimplantation genetic diagnosis (PGD) procedures to reduce the risk of genetic disorders
  • 5.2.4. Application: Wide use of preimplantation genetic testing for aneuploidy disorder
  • 5.2.5. End User: Increasing adoption of PGT in healthcare research organizations for accurate diagnosis and effective treatments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Preimplantation Genetic Testing Market, by Technology

• 6.1. Introduction
• 6.2. Comparative Genomic Hybridization
• 6.3. Fluorescence in-Situ Hybridization
• 6.4. Next-Generation Sequencing
• 6.5. Polymerase Chain Reaction
• 6.6. Single-Nucleotide Polymorphism

7. Preimplantation Genetic Testing Market, by Offering

• 7.1. Introduction
• 7.2. Instruments
• 7.3. Reagents & Consumables
• 7.4. Software & Services

8. Preimplantation Genetic Testing Market, by Procedure Type

• 8.1. Introduction
• 8.2. Preimplantation Genetic Diagnosis
• 8.3. Preimplantation Genetic Screening

9. Preimplantation Genetic Testing Market, by Application

• 9.1. Introduction
• 9.2. Aneuploidy
• 9.3. Gender Identification
• 9.4. HLA Typing
• 9.5. Single Gene Disorders
• 9.6. Structural Chromosomal Abnormalities
  • 9.6.1. Deletions
  • 9.6.2. Duplications
  • 9.6.3. Inversions
  • 9.6.4. Translocations
• 9.7. X-Linked Disorders

10. Preimplantation Genetic Testing Market, by End User

• 10.1. Introduction
• 10.2. Contract Research & Manufacturing Organizations
• 10.3. Cryobanks
• 10.4. Hospitals, Diagnostic Labs, & Service Providers
• 10.5. Research Laboratories & Academic Institutes

11. Americas Preimplantation Genetic Testing Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Preimplantation Genetic Testing Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Preimplantation Genetic Testing Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Natera Inc. to acquire prenatal and carrier screening assets from Invitae, to enhance patient services and market position
  • 14.3.2. Thermo Fisher Scientific launches advanced sequencing tools for preimplantation genetic testing, enhancing fertility research and reproductive health outcomes
  • 14.3.3. Medicover Genetics and Fimlab Laboratories Announce Partnership to Provide Genetic Testing Services in Finland
  • 14.3.4. U.S. Fertility and Ovation Combine to Create IVF Services Powerhouse, Increasing Access to Fertility Services
  • 14.3.5. Eurofins Genoma Announces Launch of niPGT-A, a Non-Invasive, Embryo Biopsy Free, Preimplantation Genetic Aneuploidy Screening
  • 14.3.6. GenEmbryomics Introduces the Most Complete IVF Genetic Test Ever Made Available
  • 14.3.7. Singaporeans Undergoing IVF to Get New Funding For Some Types of Preimplantation Genetic Testing
  • 14.3.8. Australia's Fertilis Raised USD 2 Million to Automate IVF Embryo Culturing

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. Bio-Rad Laboratories, Inc.
• 4. Bio-Techne Corporation
• 5. Bioarray S.L.
• 6. EUROPE IVF International s.r.o.
• 7. F. Hoffmann-La Roche AG
• 8. Genea Limited
• 9. GENETiKS
• 10. Illumina, Inc.
• 11. Invicta Genetics
• 12. Invitae Corporation
• 13. Juno Genetics, US Inc.
• 14. Laboratory Corporation of America Holdings
• 15. MedGenome Labs Ltd.
• 16. Merck KGaA
• 17. Natera, Inc.
• 18. NextGen Genetics Holdings, LLC
• 19. Ovation Fertility
• 20. PacGenomics
• 21. PerkinElmer, Inc.
• 22. Progyny, Inc.
• 23. Qiagen N.V.
• 24. Quest Diagnostics Incorporated
• 25. Reproductive Genetic Innovations, LLC
• 26. SEQUENCE46, LLC
• 27. Sysmex Corporation
• 28. Takara Bio Inc.
• 29. The Cooper Companies Inc.
• 30. Thermo Fisher Scientific Inc.
• 31. Vitrolife Sweden AB
• 32. Yikon Genomics (Shanghai) Co., Ltd.